: Usana sees sales bump in China, but 2023 still uncertain

Cute couple in a city. Lady in a white dress. Pair sitting on a cafe

Usana Health Sciences Inc. falls more than 4% in the extended session Thursday after the multi-level marketing company calls for lower 2023 sales and profit than Wall Street expected, saying it is unsure whether an uptick in sales at the end of 2022 will last.

You might also like